Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy Against Tumor Plasticity

C. Mehmet Hendekli

doi:10.20944/preprints202301.0421.v3

Preprint

Article

Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy Against Tumor Plasticity

This version is not peer-reviewed.

C. Mehmet Hendekli^*

This version is not peer-reviewed.

Altmetrics

Downloads

409

Views

470

Comments

Submitted:

03 March 2023

Posted:

06 March 2023

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract

Keywords:

Subject:

Medicine and Pharmacology - Oncology and Oncogenics

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Alerts

MDPI Initiatives

Important Links

Choose an area of interest and we will send you notifications of new preprints at your preferred frequency.

Disclaimer

Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune Related Adverse Events Along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy Against Tumor Plasticity

Abstract

Keywords:

Subject:

MDPI Initiatives

Important Links

Subscribe